Ally Bridge Group

Ally Bridge Group is a global life sciences investment firm founded in 2013 and headquartered in New York. It invests across both private and public markets in biotechnology, medical technology, life science tools and digital health companies, targeting innovators developing first- and best-in-class therapeutic and device solutions. The firm describes its investment premise as the point "where clinical evidence meets commercial reality".

Activity is organised around three strands: private markets investing, public markets investing and portfolio company engagement. In private markets the firm combines strategic capital with scientific expertise and commercial discipline; in public markets, investment decisions are guided by proprietary research spanning both listed and unlisted life sciences companies. Post-investment, teams work directly with portfolio companies on positioning, capital structure and exit strategy.

The investment platform draws on a team combining investment and healthcare professionals, scientists and former operators, supported by scientific advisers and operating executives. Stated objectives include elevating patient care and clinical outcomes, empowering physicians and reducing costs across the healthcare system. The firm's geographic presence is described as global.